I believe based on earlier comments, that the company was looking at alternative options to raise capital. Not sure if this means grants or deals / outlicensing or a loan via R&D tax credits.
IF the company can get funds without diluting shareholders at current prices that would be an amazing outcome. For example a $3m non capital raise now via a placement or SPP would effectively dilute current shareholders by ~30%. Whereas a grant or loan for $3m will not result in any dilution. Furthermore it will buy us time to release interim data on our clinical trial program. Boom!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $11.33K | 3.775M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 75 | 71644408 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 87927011 | 26 |
View Market Depth
| Last trade - 14.48pm 31/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |